Kamada (NASDAQ:KMDA) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Kamada Ltd. (NASDAQ:KMDA)’s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $8.04 and traded as low as $7.08. Kamada shares last traded at $7.09, with a volume of 50,074 shares traded.

Analyst Ratings Changes

Several equities analysts have recently weighed in on KMDA shares. Wall Street Zen cut Kamada from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. Weiss Ratings downgraded Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 25th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Kamada has a consensus rating of “Buy” and a consensus target price of $12.00.

Kamada Stock Performance

The stock has a market capitalization of $407.75 million, a PE ratio of 20.26, a price-to-earnings-growth ratio of 0.65 and a beta of 0.85. The business’s 50-day moving average price is $7.46 and its 200 day moving average price is $8.04.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). The business had revenue of $45.24 million during the quarter, compared to analysts’ expectations of $46.72 million. Kamada had a return on equity of 7.73% and a net margin of 11.21%. As a group, equities research analysts predict that Kamada Ltd. will post 0.44 earnings per share for the current year.

Institutional Trading of Kamada

A number of large investors have recently modified their holdings of the business. Barclays PLC grew its holdings in shares of Kamada by 417.1% during the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 3,862 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Kamada in the 4th quarter worth approximately $66,000. XTX Topco Ltd bought a new position in shares of Kamada in the 4th quarter worth $103,000. SIH Partners LLLP purchased a new stake in shares of Kamada during the 4th quarter valued at $134,000. Finally, Quadrature Capital Ltd grew its position in Kamada by 53.5% in the fourth quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock worth $155,000 after acquiring an additional 7,627 shares in the last quarter. Institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.